Nasdaq19d
OnKure Therapeutics Reports Progress on PIKture-01 Trial and Expands PI3Ka Franchise with Upcoming Development Candidate Announcement
OnKure Therapeutics updates on PIKture-01 trial progress, financial results, and expansion of PI3Ka programs, with milestones expected through 2026. OnKure Therapeutics provided an update on its ...
The Manila Times19d
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 - ...
Investing17d
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges
Relay Therapeutics specializes in developing targeted therapies for cancer patients, with a particular emphasis on precision medicines. The company’s flagship product, RLY-2608, is a PI3Ka inhibitor ...